Ipsc Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Induced pluripotent stem cell (iPSC) therapy represents a transformative approach in regenerative neurology. iPSCs are generated by reprogramming adult somatic cells (typically skin fibroblasts or blood cells) back to a pluripotent state, then differentiating them into the desired neural cell types. This technology enables patient-specific, personalized cell therapies and provides powerful disease modeling platforms.
- Differentiation into specific neuronal subtypes
- Patient-matched (autologous) or universal donor (allogeneic)
- Potential for complete functional integration
- Patient-derived neurons for drug screening
- Understanding of disease mechanisms
- Personalized drug response prediction
- Autologous cells reduce rejection risk
- Gene editing can enhance immune evasion
- Reduced immunosuppression requirements
- Dopaminergic neuron replacement
- Clinical trials initiated in Japan (2018)
- First iPSC trial for PD completed
- Long-term safety data emerging
- Motor neuron replacement
- Support cells (astrocytes, microglia)
- Early-phase trials planned
- Cholinergic neuron replacement
- Early-stage development
- Disease modeling in progress
- Striatal neuron replacement
- Preclinical validation
- Clinical translation anticipated
- Cortical neuron replacement
- Limited preclinical data
- Research ongoing
- Dual-SMAD inhibition (SB431542, LDN-193189)
- Floor plate induction
- Floor plate patterning
- Terminal differentiation
- Purification and quality control
- Dual-SMAD inhibition
- Rostralization with retinoic acid
- Caudalization with WNT activation
- Motor neuron specification
- Maturation
- Neural rosette formation
- Forebrain specification
- Cortical neuron differentiation
- Subtype specification
- First-in-human iPSC trial
- Autologous iPSC-derived dopaminergic progenitors
- Seven patients treated
- Primary endpoint: safety
- Secondary: motor function improvement
- Allogeneic iPSC for PD (multiple sites)
- iPSC for ALS (planned)
- iPSC for AD (early planning)
| Feature |
iPSC |
ESC |
Fetal NSC |
Adult NSC |
| Autologous possible |
Yes |
No |
Rare |
Sometimes |
| Unlimited source |
Yes |
Yes |
Limited |
Limited |
| Tumor risk |
Medium |
High |
Low |
Low |
| Immune rejection |
Low (auto) |
High |
Medium |
Medium |
| Differentiation |
Comprehensive |
Comprehensive |
Limited |
Limited |
| Cost |
High |
Medium |
Low |
Low |
- Genomic stability screening
- Teratoma formation testing
- Potency assays
- Identity and purity testing
- Sterility and endotoxin testing
- Scalable cell production
- Defined culture systems
- Automated manufacturing
- Cost reduction strategies
- Complex approval pathways
- IND-enabling studies
- Long-term follow-up requirements
- Tumor formation (teratoma/oncoma)
- Immune reaction (allogeneic)
- Insertional mutagenesis
- Incomplete differentiation
- Rigorous quality control
- Safety switching (tk suicide gene)
- Gene editing for immune evasion
- Comprehensive monitoring
- Universal donor iPSC banks
- Gene correction in patient-derived cells
- 3D organoid approaches
- Automated manufacturing
- Combination therapies
The study of Ipsc Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Takahashi J. Strategies for bringing induced pluripotent stem cell-based therapy to the clinic. Nat Rev Drug Discov. 2023;22(2):117-134.
- Barker RA, et al. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nat Med. 2019;25(7):1045-1053.
- Chen KG, et al. Clinical-grade human iPSC for disease modeling and regenerative therapy. Stem Cell Reports. 2021;16(11):2563-2581.
- Doi D, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell surface markers. Stem Cell Reports. 2020;15(1):154-165.
- Avior Y, et al. Pluripotent stem cells in neurodegenerative disease therapy and disease modeling. Nat Rev Neurol. 2022;18(5):267-284.